Impact Therapeutics, Inc.

This study tested a new drug called IMP4297 in 93 women with advanced ovarian cancer that has a BRCA1 or BRCA2 gene mutation and has come back after at least two prior treatments. The goal was to see if the drug can shrink tumors or slow the cancer's growth. The drug is taken as …

This study tested two different strengths (10 mg and 20 mg) of an experimental drug called IMP4297 in 36 healthy Chinese men. The goal was to see if the two strengths are processed the same way in the body after a meal. This is a bioequivalence study, meaning it checks if differe…

This completed phase 1 trial tested whether two different strengths (10 mg and 20 mg) of the experimental drug IMP4297 are processed the same way in the body. Twenty-eight healthy Chinese men each took a single dose of both strengths, with a week between doses. The study measured…

This completed Phase 1 trial studied how healthy men absorb, process, and eliminate the experimental cancer drug IMP4297. Six Chinese male volunteers took a single radioactive-labeled dose so researchers could track the drug's path. The goal was to understand the drug's metabolis…